Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. - Wikidata - wikimedia - TriplyDB

Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial.

Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial.

http://www.wikidata.org/entity/Q36467826

about

How grim is hepatocellular carcinoma?A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma.Systemic chemotherapy of liver tumors.Primary liver tumors.Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis.Systemic therapies for hepatocellular carcinoma.Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma.Combined intra-arterial 5-fluorouracil and subcutaneous interferon-alpha therapy for highly advanced hepatocellular carcinoma.Tackling hepatitis B virus-associated hepatocellular carcinoma--the future is now.Immunotherapy in hepatocellular carcinoma: Primed to make a difference?A pilot study of transcatheter arterial interferon embolization for patients with hepatocellular carcinoma.Sodium butyrate enhances STAT 1 expression in PLC/PRF/5 hepatoma cells and augments their responsiveness to interferon-alpha.Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future.Evolution of systemic therapy of advanced hepatocellular carcinoma.Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus Review article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-analysis?Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma.Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma.Recombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial

P2860

Q27001669-073A3E3B-D72E-4BC4-B91D-5E69F5DF16BC Q33493146-149BCA5F-5F92-4511-BEA9-D5F3BB360AB8 Q34110952-3F9AFC91-CFAE-4BDE-AD75-4A4B83FA0AA3 Q34110964-1773FDBA-06C8-459F-ABB4-CD0C7ADAB482 Q34998414-63B03A65-5E9B-4BD0-8885-42EA9A131816 Q35964708-9DE9BAC3-35A8-4778-8932-C9A14C26CD73 Q36671639-F574A045-995D-4F09-8A59-1B1FCCEEE883 Q36945072-1BD21916-6F44-41F0-90C6-3C0CC5AE8F34 Q38056849-DAEAA9B6-1F27-469F-961B-41B04C3A57E8 Q38625948-94D468C5-4E91-455B-B962-4C9A2F30EF75 Q40558434-27EC08E9-1A36-4537-84C1-EB9E5AAB90EF Q41814612-843AEFA8-15D2-4AFD-B218-4E381869A5A6 Q42343451-554C6C86-CD67-4CA8-8AC4-1D4A7DF42D24 Q42617015-A5E69892-8CF7-4844-8E2A-6CD27DF74F23 Q42726305-FB846E3C-33B1-4F32-9902-E29C79E4F13F Q47734769-90E74CD9-F5C2-4FE3-AB58-6ECE340CA331 Q47869247-B859C555-035D-4E33-BE3C-7ED43EAC0334 Q54234543-56262312-FEB6-488B-B324-679C7D2352D8 Q58236397-205F8239-79C5-4AA4-939D-F1C7B0CF02BC

P2860

Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial.

http://www.wikidata.org/entity/Q36467826

description

1989 nî lūn-bûn

@nan

1989年の論文

@ja

1989年学术文章

@wuu

1989年学术文章

@zh-cn

1989年学术文章

@zh-hans

1989年学术文章

@zh-my

1989年学术文章

@zh-sg

1989年學術文章

@yue

1989年學術文章

@zh

1989年學術文章

@zh-hant

name

Recombinant alpha 2 interferon ...... prospective randomised trial.

@ast

Recombinant alpha 2 interferon ...... prospective randomised trial.

@en

type

label

Recombinant alpha 2 interferon ...... prospective randomised trial.

@ast

Recombinant alpha 2 interferon ...... prospective randomised trial.

@en

prefLabel

Recombinant alpha 2 interferon ...... prospective randomised trial.

@ast

Recombinant alpha 2 interferon ...... prospective randomised trial.

@en

P1433

Q36467826-0357E5C6-B76B-46FD-A1E3-2EA33282AC35

P1476

Q36467826-352E7CE7-1E8B-4271-81B9-FBB6D9EBF151

P2093

Q36467826-0350C9F1-8FC4-43C0-99E5-492BFCCBDEDF

Q36467826-218D424A-573D-4A4C-8D65-D6A87BE46392

Q36467826-274943D0-C202-4281-BE81-B5E57D945134

Q36467826-38C06685-047E-4DE8-9271-F9BCDD524AD8

Q36467826-518B7DAD-F764-42DE-BCF3-5EC2D728F2C6

Q36467826-68353966-169C-4AD2-9767-83C335DE62A8

Q36467826-BBA27DC8-05E6-4097-96D6-443024A69957

Q36467826-BCA3BDC5-442D-440B-BEDC-11084B2D110E

Q36467826-CEE45C40-A234-47E1-BED3-8E1BEEF00644

Q36467826-CFD6E619-F335-4A58-9D89-E26B4673EED7

P2860

Q36467826-1A7BE8BC-2052-451A-B24E-BE9B7C5EF703

Q36467826-5BBFDF7C-BCD7-4317-BC1D-5CD89793AFEA

Q36467826-715EF01E-31A6-4527-9998-C96B79073C3D

Q36467826-873CF151-EC3D-4465-AEF0-5F2E17FE9E3B

Q36467826-A01783D8-D01B-4A48-8F77-4C11EE02649B

Q36467826-A5F677DC-7DA8-4D96-9F35-AD47724139E9

Q36467826-BBB48353-303B-4886-8634-B053707DE78C

Q36467826-F262DA28-D618-49D3-B508-D444ADDD224C

P2888

Q36467826-02367CB8-B5EE-4CDA-B595-4FFD37E108A0

P304

Q36467826-8B1386C8-4505-4561-ACB3-F740344110F3

P31

Q36467826-5B04FEF3-F3C3-48A6-9007-1FFB3E8D68F5

P356

Q36467826-275DCDBA-8784-455F-9907-D75BB7325FF6

P407

Q36467826-D14E215B-0CBE-4353-9FDB-EE9BFF66BD4E

P433

Q36467826-07060131-5E18-49E5-9052-2E546F3B83A9

P478

Q36467826-A562648D-98E9-4435-A5C5-3DC2655073EA

P577

Q36467826-8F4E5377-1342-4044-9A16-7D6834C9E331

P5875

Q36467826-43D90865-588D-4FC7-87B2-BCD1FD363731

P698

Q36467826-380DB408-E11D-4E9C-88E0-B6B182FCDC2A

P932

Q36467826-579C8149-A0FE-473F-859A-5DA80C993CAE

P356

P1433

British Journal of Cancer

P1476

Recombinant alpha 2 interferon ...... prospective randomised trial.

@en

P2093

Arnold M

http://www.w3.org/2001/XMLSchema#string

Chung HT

http://www.w3.org/2001/XMLSchema#string

Lai CL

http://www.w3.org/2001/XMLSchema#string

Lau JY

http://www.w3.org/2001/XMLSchema#string

Lin HJ

http://www.w3.org/2001/XMLSchema#string

Lok AS

http://www.w3.org/2001/XMLSchema#string

Ng MM

http://www.w3.org/2001/XMLSchema#string

Ngan H

http://www.w3.org/2001/XMLSchema#string

Wu PC

http://www.w3.org/2001/XMLSchema#string

Yeoh EK

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: a pilot study.

NIH conference. Hepatocellular carcinoma.

Clinical features of hepatocellular carcinoma: review of 211 patients in Hong Kong.

alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma.

Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results.

Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer.

Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers.

Primary hepatocellular carcinoma--etiology, pathogenesis, and prevention.

P2888

P304

928-933

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.1989.392

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P577

1989-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

20598034

http://www.w3.org/2001/XMLSchema#string

P698

2557881

http://www.w3.org/2001/XMLSchema#string

P932

2247256

http://www.w3.org/2001/XMLSchema#string